Part of Evogene
Clinical Trials
1
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2016
Active, not recruiting
1
100.0%
No approval data available
- Biomica, Evogene's subsidiary, has licensed BMC128, a first-in-class microbiome-based therapeutic, to Shanghai Lishan Biopharmaceuticals for global development and commercialization. - BMC128 is completing Phase 1 trials in renal cell carcinoma and non-small cell lung cancer, demonstrating excellent safety profile and early efficacy signs with stable disease achieved in previously progressive patients. - Lishan Biotech will advance BMC128 into Phase 2 studies and pursue regulatory filings in China and the United States, while Biomica receives milestone payments and royalties. - The live biopharmaceutical consortium consists of four human gut bacterial strains designed to enhance immunotherapy responses and stimulate anti-tumor immune activity.
- Evogene Ltd. has completed its generative AI foundation model version 1.0 for small molecule design, developed in collaboration with Google Cloud, achieving approximately 90% precision compared to 29% in traditional GPT AI models. - The model addresses the core challenge of identifying novel small molecules that simultaneously meet multiple complex product criteria while being patentable, essential for both pharmaceutical and agriculture applications. - Built on a dataset of approximately 38 billion molecular structures and trained using Google Cloud's advanced AI infrastructure, the model expands ChemPass AI capabilities to generate truly novel molecular structures. - Development is already underway on version 2.0 with enhanced flexibility for multi-parameter optimization, incorporating customized parameters tailored to therapeutic contexts and specific agriculture requirements.
